According to filings with the U.S. Securities and Exchange Commission, Gallant Pet is raising up to $27,056,368.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Linda Black played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Gallant Pet
Gallant Therapeutics is a clinical-stage animal health biotechnology company setting a new standard in animal health by harnessing the power of stem cell therapy to treat the root cause of diseases in dogs and cats. Our pipeline of off-the-shelf mesenchymal stem cell (MSC) therapies has the potential to treat a broad range of diseases, including canine and feline osteoarthritis (OA), feline chronic kidney disease (CKD), and others. The first product based on our uterine-derived platform for feline chronic gingivostomatitis (FCGS), is on track for conditional approval by the FDA in 2025. United by a love of and commitment to animals, Gallants team includes industry pioneers in veterinary regenerative medicine with deep experience in cell therapy product development, manufacturing and commercialization.

To learn more about Gallant Pet, visit http://gallant.com/
Gallant Pet Linkedin Page: https://www.linkedin.com/company/gallanttherapeutics/

Contact:
Linda Black, Chief Executive Officer
310-294-2700
https://www.linkedin.com/in/lindablackdvmphd/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.